← Novavax, Inc. (NVAX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Novavax, Inc. (NVAX)
Biological Products, (No Diagnostic Substances) · market cap $1.8B · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
20
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Novavax, Inc. (NVAX) is a Gaithersburg, Maryland-based vaccine developer best known for its protein subunit COVID-19 vaccine NVX-CoV2373, which is now commercialized through a partnership with Sanofi. With 952 employees, a $1.35B market cap, and a broad pipeline spanning COVID-19, influenza, RSV, and pandemic preparedness, the company posted $1.12B in revenue in 2025 and returned to net profitability ($440M net income) after years of deep losses. Cash of $228M provides roughly 21 months of runway, and net debt stands at $62.7M.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| RSV F vaccine (0.5mL injection) | Phase 2 | Respiratory Syncytial Virus Infections |
| NVX-CoV2373 (5μg) | Phase 3 | COVID-19 |
| XBB.1.5 Vaccine (Booster) | Phase 3 | COVID-19 |
| SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period) | Phase 3 | COVID-19 |
| NVX-CoV2705 Vaccine | Phase 3 | Severe Acute Respiratory Syndrome Coronavirus 2 Infection |
| SARS-CoV-2 rS/Matrix M1-Adjuvant | Phase 3 | SARS-CoV-2 Infection |
| Influenza VLP Vaccine | Phase 2 | Influenza |
| NanoFlu | Phase 3 | Influenza, Human |
| SARS-CoV-2 rS - Phase 1 | Phase 2 | COVID-19 |
| Quadrivalent VLP Vaccine | Phase 2 | Influenza |
| RSV-F Vaccine | Phase 3 | Respiratory Syncytial Virus (RSV) |
| Influenza VLP Vaccine (recombinant) | Phase 2 | Influenza |
| H5N1 VLP Vaccine | Phase 2 | Pandemic Influenza |
| ICC Vaccine | Phase 2 | SARS-CoV Infection |
| Low dose RSV F Antigen | Phase 2 | Respiratory Syncytial Virus Infections |
| Novavax Quadrivalent vaccine | Phase 2 | Influenza |
| Low dose RSV-F Vaccine with Adjuvant | Phase 2 | Respiratory Syncytial Virus (RSV) |
| qNIV Vaccine with Matrix-M Adjuvant | Phase 2 | COVID-19 |
| A/H1N1 2009 Influenza VLP Vaccine | Phase 2 | Seasonal Influenza |
| NVX-CoV2373 | Phase 3 | SARS-CoV-2 Infection |
Price & technical context
3-month
+8.8%
6-month
+32.2%
12-month
+22.3%
52-wk range
$6.22–$11.19
vs 50-day MA
+17.2%
vs 200-day MA
+19.5%
Realized vol
62.5%
Max drawdown
-63.0%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for NVAX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.